

Review

The Role of Thrombospondins in Osteoarthritis: from Molecular Mechanisms to Therapeutic Potential

Yirixiati Aihaiti^{1,2}, Hui Yu², Peng Xu^{1,2}

1. Department of Joint Surgery, Xi'an Jiaotong University Affiliated HongHui Hospital, Xi'an, China.

2. Key Laboratory of Pathogenesis and Precision Treatment of Arthritis, Xi'an, ShaanXi province, China.

 Corresponding author: Department of Joint Surgery, Xi'an Jiaotong University Affiliated HongHui Hospital, 710000, Xi'an, Shaanxi Province, China. E-mail address: erxatahat@126.com (Y.A.).© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>). See <https://ivyspring.com/terms> for full terms and conditions.

Received: 2024.09.06; Accepted: 2024.11.28; Published: 2025.03.03

Abstract

Osteoarthritis (OA) is a prevalent chronic degenerative joint disorder characterized by cartilage degeneration, joint inflammation, and pain. The pathogenesis of OA still remains unclear. Among the various factors contributing to OA, the role of extracellular matrix (ECM) proteins, particularly thrombospondins (TSPs), has garnered significant attention. TSPs, a family of multifunctional extracellular matrix glycoproteins, are known to participate in numerous physiological and pathological processes, including cell adhesion, migration, differentiation, angiogenesis, and synaptogenesis through cell-cell and cell-matrix interactions. In this review, we provide a summary of the current understanding of TSP proteins in the pathogenesis of OA, including their effects on cartilage homeostasis, synovial inflammation, and subchondral bone remodeling and arthritic pain. We also review the evidence supporting the potential of TSP proteins as diagnostic biomarkers and therapeutic targets, with a focus on recent advances in cartilage regeneration, gene delivery therapy and pain management. Considering the multifaceted roles of TSP proteins in maintaining articular homeostasis, TSP proteins emerge as promising therapeutic targets for OA.

Keywords: osteoarthritis, thrombospondin, extracellular matrix

1. Introduction

Osteoarthritis (OA) is one of the most prevalent degenerative diseases among the elderly, characterized by progressive cartilage loss, osteophyte formation, chronic synovitis, and recognized as a leading cause of musculoskeletal disability worldwide. OA primarily affects weight-bearing joints, such as the knee and hip, presenting with clinical manifestations including gradually increasing joint pain, swelling, stiffness, and reduced mobility [1]. In advanced stages, it can lead to joints deformity and disability. The etiology of OA remains unclear; however, genetic factors, anatomical abnormalities, sex, obesity, and trauma have been identified as risk factors [2]. The global aging trends observed today have led to a rapid increase in the incidence of OA, affecting approximately 300 million individuals globally, with a higher prevalence in females [3]. The current

approach to OA treatment primarily aims to alleviate joint pain, improve joint function, slow disease progression, correct joint deformities, and consider joint replacement surgery as a last resort for end-stage disease due to the limited availability of disease-modifying osteoarthritis drugs (DMOADs) [4]. Therefore, understanding the pathogenesis of OA is crucial for identifying diagnostic biomarkers and therapeutic targets at various stages of the disease, which can help arrest disease progression, improve patients' quality of life, and reduce strain on healthcare systems.

In recent decades, there has been a paradigm shift in the understanding of OA pathogenesis, transitioning from perceiving it as a mere 'wear and tear' effect on weight-bearing joint cartilage to recognizing it as a chronic disorder that impacts the entire joint. This includes cartilage degeneration,

structural changes in subchondral bone, formation of osteophytes, synovial inflammation, as well as tendon and ligament degeneration (Figure 1). Aberrant extracellular matrix (ECM) remodeling is closely related to the pathogenesis of OA [5]. ECM is an intricate acellular, three-dimensional structural network that is ubiquitously present in almost all tissue [6]. The role of the ECM extends beyond providing biomechanical support to cells, tissues, and organs; it also maintains homeostasis of microenvironment through regulating numerous biological processes, including cellular adhesion, migration, differentiation, and growth [7]. Thrombospondin (TSP) is a family of extracellular oligomeric glycoproteins consists of five distinct conserved members (TSP-1,2,3,4 and 5) [8]. TSPs serve as not only structural proteins, but also contribute to tissue repair, angiogenesis, synaptogenesis, and tissue inflammation through mediating cell-ECM interactions [9]. Despite being discovered over 40 years ago, specific roles of TSPs in the musculoskeletal system remain incompletely understood, with ongoing discoveries shedding new light. Therefore, a comprehensive review is required to clarify the physiological functions and molecular mechanisms of TSPs in the pathogenesis of OA. This review provides a thorough discussion regarding the involvement of TSPs in the pathological alterations during OA, emphasizing their potential as diagnostic biomarkers and therapeutic targets for OA. We also highlight the challenges and opportunities involved in translating these findings into clinical practice.

2. Structure and biological functions of thrombospondins

Structurally, the TSP family is classified into two subgroups [10]. Subgroup A consists of TSP-1 and TSP-2, both possessing a trimeric structure and demonstrating similar functional properties. On the other hand, subgroup B consists of TSP-3, TSP-4, and TSP-5, which possess a pentameric structure (Figure 2). The TSP subunits possess a conserved feature of a C-terminal domain that contains tandem calcium-binding TSP type III repeats, three (TSP-1 and TSP-2) to four (TSP-3, TSP-4 and TSP-5) type II epidermal growth factor-like (EGF-like) repeats, as well as a carboxy-terminal domain structurally homologous to the L-type lectin domain. The C-terminal domain represents the distinctive hallmark of the TSP family [11], displaying a robust binding affinity to both collagenous and non-collagenous extracellular matrix proteins, thereby serving as a fundamental scaffold in the assembly of the collagen network [12]. The N-terminal halves of TSP are much more varied in domain structure and

sequence. The amino-terminal domains of subgroup A are identical and consist of an oligomerization domain, a von Willebrand factor type C (VWC) domain along with three thrombospondin-type I repeats (TSRs), the subgroup B lacks both vWC domains and TSRs [8]. Additionally, TSP-5 lacks a typical amino-terminal domain [13]. Due to the multiple structural domains, TSP proteins exhibit various functions through binding with different cell surface receptors and ECM proteins. The VWC domains and TSRs in TSP-1 and TSP-2 exert antiangiogenic activity by binding to CD36 (a transmembrane glycoprotein) [14]. In addition, TSRs are necessary for binding and activation of transforming growth factor (TGF)- β family. EGF-like domains are employed for regulation of cell adhesion and migration through binding of integrins and Ca^{2+} . The C-terminal domain of TSP harbors a CD47 binding site, which consequently inhibits endothelial nitric oxide synthase (eNOS) activation and angiogenesis [8]. TSP proteins are widely distributed in various tissues and organs including bone, cartilage, tendon, ligament, smooth muscle and synovial tissue, and exhibit a specific spatiotemporal distribution during the embryo development. Findings from knockout mice have revealed the specific physiological roles of TSP proteins in skeleton and cartilage development (Table 1) (extensive review for the modulation of TSPs in skeleton development, please refer to the reviews authored by Kurt D. Hankenson [15; 16]). The expression levels of TSP proteins are low in normal tissues, but significantly increases following tissue injury, indicating the involvement of TSPs in the inflammatory response and the subsequent tissue remodeling including fracture healing, cartilage regeneration, and wound healing [17]. Numerous studies have demonstrated the involvement of TSPs in the pathological progression of cardiovascular diseases, tumor genesis, metastasis and therapies response [17; 18]. An in-depth exploration of the precise mechanisms through which TSPs participate in OA progression is crucial for the development of novel therapeutic strategies.

3. The role of Thrombospondins in the pathogenesis of OA

3.1. Thrombospondins in cartilage homeostasis and degeneration

The degeneration of cartilage is widely acknowledged as the hallmark feature of OA. The articular cartilage is composed of chondrocytes that are embedded within a highly organized ECM consisting of collagen fibers, proteoglycans,

glycoproteins, and interstitial water [28]. Type II collagen serves as the primary structural component of cartilage, forming a highly crosslinked fibrous network that imparts both support and tensile strength to the tissue. This robust framework is further reinforced and stabilized by the presence of minor collagens, such as types IX and XI, which integrate into the network to enhance its functional integrity [29]. The major proteoglycan aggrecan imparts elasticity and resistance to compression for cartilage through the osmotic pressure and negative charge of its glycosaminoglycan side chains (chondroitin sulfate and keratin sulfate) [30]. Apart from these structural proteins, the complex collagenous network also contains non-structural glycoproteins, such as perlecan, decorin and fibronectin [30; 31; 32], primarily responsible for binding to collagen and proteoglycans, thereby enhancing the stability of the collagen network and facilitating the chondrogenesis through cell-cell and cell-matrix interactions. The TSP family is also classified as a group of nonstructural glycoproteins within articular cartilage and has been investigated as crucial factors in both the development and

degradation of cartilage. The expression and distribution patterns of TSP proteins exhibit variations throughout the process of chondrogenesis, suggesting their distinct and specific roles in the development of cartilage, as well as important biomarkers for chondrocyte differentiation. Farrell *et al.* [33] investigated the distribution pattern of TSP-5 and TSP-4 during growth plate maturation in mice, revealing that TSP-5 predominantly localized around columnar chondrocytes within the proliferation zone and hypertrophic zone of naive cartilage. Starting from postnatal day 7, a widespread distribution of TSP-5 was observed across all layers of cartilage until endochondral ossification occurred. The pericellular localization of TSP-4 was consistently observed in the hypertrophic zone throughout the maturation process of the growth plate, exhibiting a distribution pattern similar to that of COL-X [33]. The expression of TSP-2 was predominantly observed in the majority of proliferating chondrocytes within the femoral head and acetabulum on day 15 of embryonic mouse tissue. On day 18, TSP-2 was localized to the perichondria of developing bones such as basioccipital, scapula, and ulna [34].

Table 1. Overview of skeletal and articular cartilage phenotypes in Thrombospondins knockout mice

Knockout gene	Skeleton phenotype	Articular cartilage phenotype	Ref.
TSP-1	Increased cancellous and cortical bone mass Mild lordotic curvature of the spine; craniofacial dysmorphism	growth plate disorganization	[19; 20]
TSP-2	Increased endosteal bone thickness in adult mice; exhibited a brittle phenotype on cortical bone associated with changes in collagen fibrillogenesis. Accelerated vascularization and bone formation at the fracture site	Reduced Col2a and Sox9 expression, reduced cartilage formation at the fracture site.	[21; 22; 23]
TSP-3	Acceleration in the rate of femoral head endochondral ossification	Increased hypertrophy in growth plate chondrocytes; growth plate disorganization	[24; 25]
TSP-4	No phenotypic differences were observed	Transient thinning of articular cartilage, but no significant effects on cell proliferation, metabolism and apoptosis	[26]
TSP-5	Pseudoachondroplasia; multiple epiphyseal dysplasia; joint abnormalities and short stature	Growth plate disorganization; Decreasing in the number of growth plate chondrocytes; early onset of OA	[25; 27]




Figure 1. Pathological alterations of OA. The pathogenesis of OA involves the degeneration of cartilage, inflammation of the synovium, subchondral bone formation.




Figure 2. Structure and biological functions of TSPs. TSP family consists of five members (TSP-1, -2, -3, -4, and -5) which are classified into two subgroups. Subgroup A (trimer) comprises TSP-1 and TSP-2, while subgroup B (pentamer) consists of TSP-3, TSP-4, and TSP-5. The TSP subunits possess a conserved feature of C-terminal domain contains CD47 binding site. TSP type III repeats are involved in angiogenesis through binding with Ca²⁺, integrins, and elastase. Type II epidermal growth factor-like (EGF-like) repeats are employed for regulation of ECM synthesis, migration, and excitatory synaptogenesis through binding with integrins, Ca²⁺, and Ca_vα₂δ₁. The Von Willebrand factor type C (vWc) domain and type I repeats only exist in subgroup A and exhibit antiangiogenic activity by binding to CD36, and are implicated in binding and activation of TGF-β family. The N-terminal domains are much more varied in structure and sequence. TSP-5 lacks a typical amino-terminal domain. The coiled-coil oligomerization domain is responsible for homooligomers formation.

TSP-1 protein was present in the pericellular and interterritorial cartilage matrix of the middle and upper deep zones [35]. TSP-3 transcripts were observed in only differentiated chondrocytes [36]. Functionally, TSP family participates in the maintenance of cartilage homeostasis through various signaling pathways. An in-vitro study using porcine chondrocytes demonstrated that TSP-5 and TSP-4 facilitate collagen and proteoglycan synthesis, thereby preserving the phenotype of chondrocytes through activating TGF-β-induced Erk1/2 signaling pathway, additionally, TSP-5 promotes chondrocyte migration and attachment [37]. TSP-1 maintains cartilage homeostasis by promoting chondrocyte proliferation and extracellular matrix synthesis, inhibiting apoptosis, and enhancing autophagy in IL-1β-induced chondrocytes [38]. Relevant to this discovery, collagen content was significantly decreased in hearts of TSP-1 null mice, leading to enhanced production of MMP-3 and MMP-9 under pressure overloading conditions, consequently, resulted in early cardiac hypertrophy and dilation [39]. TSP-2 null mice display connective tissue abnormalities, including irregular collagen fibrillogenesis, which may affect the structure and function of cartilage [34]. TSP proteins may also serve as diagnostic biomarkers for OA, as their expression exhibited significant disparities between OA patients and healthy individuals. The expression of TSP-5 was

consistently observed throughout all layers of normal cartilage, whereas the expression of TSP-4 was minimal [33]. Conversely, the expression of TSP-4 was significantly increased in OA cartilage, whereas the TSP-5 was notably degraded [37]. The expression of TSP-4 is correlated with disease severity of OA cartilage [40]. TSP-4 can be detected in the serum of both healthy individuals and OA patients. Notably, amounts of TSP-4 fragments are specifically increased in the serum of OA patients, suggesting its potential in serological marker for OA diagnosis. In mild to moderate OA cartilage, an increased number of TSP-1 expressing chondrocyte were observed in the superficial region. As the degradation of matrix in severe OA cartilage, a strong reduction of TSP-1 producing chondrocytes and increased number of CD36 (a classical TSP-1 receptor) positive chondrocyte were observed [35]. Similarly, in a rat model of OA, the expression of TSP-1 gradually decreases in articular cartilage along with disease progression. Additionally, the serum levels of TSP-1 also exhibit a decrease starting from 60 days after ACLT surgery [38]. Moreover, TSPs also show promising potential as therapeutic targets for OA. Intraarticular injection of adenoviral carrying TSP-1 cDNA effectively attenuated OA progression by down-regulating MMP-13 expression in cartilage and reducing microvessel density and macrophage infiltration in

synovial tissue [41]. Collectively, the TSPs serve as crucial components of ECM and play a significant role in maintaining cartilage homeostasis.

3.2. Thrombospondins in synovial inflammation

The majority of patients with OA commonly present symptoms of synovitis, the presence of which is associated with the progressive deterioration of OA joint [42]. In normal joint cavity, synovial tissue typically consists of 1-3 layers of synoviocytes forming a protective covering over the inner lining surface of the joint capsule, participating in maintaining articular homeostasis. Resident synoviocytes primarily consist of macrophage-like synoviocytes (MLSs) and fibroblast-like synoviocytes (FLSs). The main functions of MLSs include phagocytosis of debris from cartilage and meniscus, as well as immunoregulation. FLSs possess the ability to secrete hyaluronic acid (HA)-enriched synovial fluid, providing nourishment to cartilage and facilitating joint lubrication [43]. Histopathologically, OA synovium demonstrates mild-to-moderate inflammation characterized by synovial lining hyperplasia, pannus formation, and immune cells infiltration [44]. The level of immune cells infiltration in the synovial tissue of patients with OA is comparatively lower than that seen in individuals with rheumatoid arthritis (RA), but higher than what is observed in healthy individuals [45]. The application of single cell RNA (sc-RNA) sequencing has also unveiled the existence of diverse immune cells within OA synovial tissue [46; 47]. The expression of TSPs in OA synovial tissues exhibit significant difference compared to those observed in normal synovial tissues, as evidenced by multiple researches (Table 2). Maerz *et al.* utilized single cell RNA sequencing to identify patterns of outgoing cellular communication of TSPs within the synovium of OA mice, suggesting that TSPs may serve as important signaling molecules in the pathogenesis of OA [48]. In addition to preserving cartilage integrity, TSP-1 exerts anti-arthritic effect by inhibiting angiogenesis and macrophages infiltration through activating TGF- β production in OA synovial tissue [41]. However, in a contrasting conclusion, Decana *et al.* observed an increase of TSP-1 protein expression in the inflammatory synovial tissue from rat model of RA, and TSP-1 protein expression were positively correlated with articular destruction severity. Interestingly, treatment with TSP-1-derived peptide not only inhibited TSP-1 expression but also decreased pannus formation, neovascularization, inflammatory cells infiltration and cartilage destruction in articular joint [49; 50]. The plasma

samples from RA patients also exhibited elevated levels of circulating TSP-1 protein [51]. Similarly, the expression of TSP-2 was significantly upregulated in OA-FLSs, exhibiting a positive correlation with inflammation level in synovial tissue. Elevated TSP-2 expression in OA-FLSs promotes IL-6 production by activating PI3K/AKT/NF- κ B signaling pathway. Targeted therapy with a neutralizing antibody against TSP-2 attenuates articular cartilage degradation and suppressed IL-6 production in OA mice [52]. Despite being known as angiogenesis inhibitors (to be discussed in 3.4), both TSP-1 and TSP-2 appear to function as pro-inflammatory mediators that promote synovial hyperplasia, cartilage degeneration and immune cells infiltration in synovial tissues. MLSs are the main source of inflammatory cytokines in OA joints, as the pro-inflammatory macrophages (M1) accumulate more in OA synovial tissue, promoting cartilage degradation through secreting pro-inflammatory cytokines, such as IL-1 β , IL-6, and TNF- α [53]. Modulating the polarization of synovial macrophages presents a promising therapeutic approach for OA. Previous studies have demonstrated the regulatory roles of TSPs in modulating macrophage polarization, with distinct members exhibiting diverse functions. The expression of TSP-4 is significantly increased upon the stimulation of pro-inflammatory cytokines (LPS, IFN γ , and GM-CSF) in bone marrow-derived macrophages (BMDM), furthermore, deficiency of TSP-4 promotes the polarization of BMDM into anti-inflammatory phenotype (M2), as evidenced by increased expressions of Egr-2 and Arg-1 [54]. Targeted inhibition of TSP-4 in macrophages within the inflammatory site has the potential to attenuate inflammation and promote tissue regeneration by promoting M2 macrophages polarization. TSP-2 promotes M2 macrophages polarization and inhibits apoptosis in murine alveolar macrophage cell through activating PI3K/AKT signaling pathway [55]. However, TSP-1 exhibits dual roles in macrophages, exerting both pro-inflammatory and anti-inflammatory functions, on the one hand, TSP-1 stimulates TNF- α production in macrophages through activating Toll-like receptor. Macrophage-specific Tsp-1 deletion protects mice against non-alcoholic fatty liver disease through reducing liver inflammation and fibrosis [56; 57]. On the other hand, TSP-1 also acts as an inhibitor of local inflammatory response while facilitating tissue repair through the promotion of M2 macrophage polarization [58]. Further investigation is warranted to elucidate the specific roles of TSP proteins in OA synovial inflammation, thereby offering potential therapeutic targets for the treatment of OA.

Table 2. Summarizing the role of thrombospondins in inflammatory response related to OA and RA.

Gene	Disease	Cell source	Expression pattern	Intervention	<i>In-vivo</i> model	Outcome	Ref.
TSP-1	OA	-	Decreased TSP-1 in synovium and synovial fluid from OA rats	Intraarticular injection of TSP-1 adenovirus.	ACLT induced OA rats	Reduced angiogenesis, inflammation, macrophage infiltration, and cartilage degradation; Inhibited T lymphocyte proliferation.	[41; 59]
	RA	FLSs from RA patients	Increased TSP-1 in synovium and plasma from RA patients	Intraperitoneal injection of TSP1-derived peptide	Peptidoglycan-polysaccharide induced erosive arthritis in rats	TSP1-derived peptide reduced inflammation, angiogenesis and pannus formation; TNF- α inhibitors restored TSP-1 levels and reduce inflammation.	[50; 51; 60]
	Obesity related inflammation	BMDMs and human macrophages	Increased TSP-1 in developing adipose tissue from obese mice and humans.	Treatment with recombinant TSP-1	Wild-type and TLR4-deficient mice	TSP-1 activated TLR4 signaling in macrophages and induced TNF- α production	[57]
TSP-2	OA	FLSs from OA patients	Increased TSP-2 expression compared to normal synovial fibroblasts.	TSP2-neutralizing antibody	ACLT induced OA rats	TSP2 activated the PI3K/ Akt/NF- κ B pathway through integrin α v β 3, inducing IL-6 and inflammation, while its neutralizing antibodies reduced cartilage damage and inflammation.	[52]
	RA	FLSs from RA patients	Decreased TSP-2 expression in RA synovium.	Overexpression of LINC01197 (which sponges miR-150 to promote TSP-2 expression); miR-150 mimic; TSP-2 overexpression	Collagen-induced arthritis RA mice	TSP-2 overexpression inhibited RA-FLS proliferation and inflammatory responses; TSP-2 expression was increased by LINC01197, leading to reduced RA severity, swelling, and inflammation in RA mice.	[61]
TSP-4	Acute inflammation and peritonitis	BMDMs and RAW264.7 cells	Increased TSP-4 expression under the stimulation of LPS, GM-CSF and IFN- γ .	TSP-4 knockout mice	C57BL/6 mice with LPS-induced peritonitis	TSP-4 promoted pro-inflammatory macrophages polarization	[54]

3.3. Thrombospondins in uncoupled subchondral bone remodeling

Subchondral bone refers to the subchondral bone plate and subchondral bone trabecula distal to the tidemark of articular cartilage. The subchondral bone is the essential mechanical and nutritional support system of joints, maintaining the integrity and biological function of overlying cartilage [62]. Under physiological conditions, subchondral bone remodeling is exquisitely regulated by osteoblasts-mediated bone formation and osteoclasts-mediated bone resorption [63]. Distinct microstructural alterations occur in the subchondral bone at different stages of OA, even prior to the development of significant cartilage damage [64]. In the early stage of OA, the number of osteoclasts markedly increases within subchondral bone, and the ratio of receptor activator of nuclear factor κ ligands (RANKL)/ osteoprotegerin (OPG) was elevated in osteocytes, thereby inducing the osteoclastogenesis and bone resorption [65; 66; 67]. As a result, subchondral bone becomes porous with enlargement of trabecular gap and bone marrow cavity, decrease in subchondral bone plate thickness. Bone marrow edema, bone cyst and microfractures in subchondral bone can be detected through imaging examination [1; 68]. Osteoclasts are multi-nucleated giant cells formed from the fusion of multiple monocytes/ macrophages, exhibiting positive staining for tartrate-resistant acid phosphatase (TRAP). Osteoclasts precursor cells differentiate into mature osteoclasts under the

stimulation of macrophage colony-stimulating factor (M-CSF) and RANKL, with M-CSF promoting their proliferation and RANKL promoting their differentiation [69]. The recruitment, differentiation, and activation of osteoclasts in early OA are primarily attributed to aberrant biomechanical and biochemical factors [70], however, the underlying mechanism remains unclear. TSP proteins have been assigned for multiple functions in osteoclastogenesis through binding with specific ligands (Figure 3). In a co-culture system with myeloma cells, immature dendritic cells transdifferentiate into TRAP-positive bone-resorbing multi-nucleated giant cells with significant upregulation of TSP-1 expression. Meanwhile, autocrine secretion of TSP-1 by osteoclasts precursors binds to CD36 and CD47, resulting in the inhibition of nitric oxide synthesis and promotion of monocyte fusion and osteoclastogenesis [71; 72; 73]. Neutralizing antibody against TSP-1 addition led to significant inhibition of parathyroid hormone (PTH) induced hypercalcemia, osteoclasts formation and bone resorption both *in-vitro* and *in-vivo* [74]. Consistently, TSP-1 knockout mice exhibited elevated bone mass and cortical bone size, accompanied by reduced bone resorption and osteoclasts formation, as well as increased expressions of inducible nitric oxide synthase (iNOS) [20]. Lung cancer patients with high TSP-2 expression exhibited an increased susceptibility to bone metastasis [75]. Lung cancer-secreted TSP-2 facilitates the RANKL-dependent osteoclasts formation in murine osteoclasts precursor RAW264.7 cells by activating

NFATc1 and suppressing miR-486-3p expression, also modulating the RANKL/OPG ratio in osteoblasts. The inhibition of TSP-2 expression significantly impedes the bone metastasis of lung cancer cells *in-vivo* [76]. Relatively, little is known about contributions of other TSP proteins in the process of osteoclastogenesis. The transient activation of osteoclasts leads to an increase in trabecular gap and bone marrow cavity, thereby promoting angiogenesis and innervation of the subchondral bone, concurrently stimulating osteoblastic bone formation through releasing transforming growth factor- β (TGF- β) from bone matrix [68; 77]. Therefore, in the late stages of OA, subchondral bone is mainly characterized by osteoblasts-mediated bone formation, as evidenced by imaging examination revealing subchondral bone sclerosis and osteophytes formation [1]. Subchondral bone in advanced OA patients demonstrates increased bone density, bone volume, and collagen content, as well as decreased calcium to collagen ratio, bone mineralization, and mechanical stiffness [78; 79; 80]. TGF- β plays an important role in bone formation, through increasing osteoprogenitors proliferation and maturation, while inhibiting late stage osteoblast differentiation and

bone matrix mineralization [81]. TGF- β expression is significantly upregulated in the subchondral bone of both OA patients and mouse model of OA, leading to enhanced recruitment and osteogenic differentiation of mesenchymal stem cells (MSCs) within the subchondral bone [82]. The regulation of TGF- β primarily occurs during the conversion of its latent precursor into the biologically active molecule. Specifically, the binding of the N-terminal latency-associated peptide (LAP) impedes TGF- β from engaging with its receptors, and it is imperative to disrupt this interaction for TGF- β signaling activation [83]. TSP-1 is a major regulator of latent TGF- β activation, the KRFK sequence in TSP-1 type 1 repeats binds to a conserved sequence, LSKL, in LAP, disrupting LAP-mature domain interactions and activating TGF- β through exposing its receptor binding sequences (reviewed in [19]). Aesculetin, a coumarin derivative, enhances osteogenic differentiation and bone matrix mineralization in the MC3T3-E1 cell line. Notably, aesculetin significantly accelerates the synthesis of TSP-1 and tenascin C in mature osteoblasts, facilitating their adhesion to preformed collagen matrix [84].




Figure 3. The role of TSPs in bone remodeling. In early-stage OA, subchondral bone is mainly characterized by osteoclasts-mediated bone resorption. Subchondral bone becomes porous with enlargement of trabecular gap and bone marrow cavity. Angiogenesis and sensory innervation were increased within subchondral bone. The TSPs play different roles in osteoclastogenesis. TSP-1 activates osteoclastogenesis through promoting proliferation and fusion of osteoclasts precursors, additionally, it acts as a major regulator of latent TGF- β activation released during bone resorption. TSP-2 facilitates the fusion of osteoclasts precursors and RANKL-dependent osteoclasts formation. In late-stage OA, subchondral bone is mainly characterized by osteoblast-mediated bone formation. Subchondral bone demonstrates increased bone density, bone volume, as well as decreased calcium to collagen ratio, bone mineralization, and mechanical stiffness. TSP-2 inhibits the proliferation and adipogenic differentiation of MSCs, and promotes osteogenic differentiation and bone deposition. TSP-1 and TSP-5 promote MSCs proliferation and osteogenic differentiation through activating TGF- β /smad signaling pathway.

Therefore, the authors hypothesized that TSP-1 may participate in OA subchondral bone remodeling through activating TGF- β and promoting the osteogenic differentiation of MSCs, resulting in increased bone volume but decreased bone mineralization and mechanical stiffness in subchondral bone. By inhibiting the activity of TSP-1, it is possible to block the activation of TGF- β and potentially restore the uncoupling subchondral bone remodeling, thus presenting a potential therapeutic target for OA. Hankenson KD et. al demonstrated that MSCs from TSP-2-null mice exhibited increased proliferation and adipogenesis, decreased terminal osteoblastic differentiation, collagen fibrillogenesis and mineralization *in vitro*, suggesting that TSP-2 promotes osteoblasts differentiation and bone deposition *in vitro* [85; 86; 87; 88]. Their *in vivo* findings demonstrated a significant upregulation of TSP-2 expression during the process of fracture healing. Additionally, TSP-2 deficient mice exhibited an increased formation of endocortical bone and cortical thickness due to an enhanced proliferation of osteoblasts progenitors. Moreover, TSP-2-null mice displayed augmented vascularization and a shift towards an intramembranous healing phenotype in ischemic fracture [23]. They also observed that the mutation of TSP-2 provides protection against ovariectomy-induced bone loss through increasing osteoblastogenesis and inhibiting bone resorption [89]. Bone morphogenetic proteins (BMP-2), also a member of TGF- β family, has been clinically applied for nonunion and lumbar body fusions [90]. However, the application of BMP-2 is limited due to the requirement of supraphysiological doses [91]. D.R. Haudenschild and colleagues revealed that TSP-5 also exhibits binding affinity towards TGF- β family, including TGF- β 1 [92] and BMP-2 [93], thereby enhancing the osteogenesis through activation of TGF- β /smad signaling pathway, this binding interaction reaches its maximum potency under mildly acidic (pH 5.50-6.50) conditions with the presence of manganese [93]. Comparison of the secretome from osteoblasts derived from sclerotic and non-sclerotic subchondral bone in OA patients revealed a significant reduction in the secretion of TSP-4 by osteoblasts from the sclerotic region [94]. In contrast, Michael *et al.* reported a significant increase in TSP-4 mRNA expression during the osteoblastic differentiation process of primary murine osteoblasts [26]. Additionally, Sofat *et al.* employed high throughput microarray analysis to investigate the genetic alterations in the subchondral bone marrow lesion (BML) from advanced OA, mild OA and normal individuals. Their findings revealed a striking increase of TSP-4 expression in BML regions of OA

patients, accompanied by significant activation of pathways associated with angiogenesis (see in 3.4), pain sensitization (see in 3.5) [95]. However, the specific roles of TSP-4 in regulation of osteoclasts and osteoblasts differentiation remain unclear. Collectively, these findings provide support for the distinct roles of TSPs in maintaining bone homeostasis. The aberrant expression of TSPs in the pathogenesis of OA may serve as a pivotal factor influencing subchondral bone remodeling.

3.4. Thrombospondins in angiogenesis

Angiogenesis consistently accompanies subchondral bone remodeling in the pathogenesis of OA. A distinct subtype of blood vessels, known as type H vessels, was identified in the trabecular bone adjacent to the growth plate and exhibited a notable expression of CD31 and endomucin (Emcn) [70; 96]. In addition to oxygen supply, type H vessels are highly coupled with bone formation activities by attracting a large amount of osteoprogenitors around, regulating the osteoblasts differentiation [97]. The balance between proangiogenic and antiangiogenic activities in subchondral bone is distributed during the pathogenesis of OA. In 60% of patients with OA, blood vessels breach the tidemark and infiltrate into avascular cartilage and meniscus, while vascular density within subchondral bone increases with disease progression and shows a positive correlation with histological severity score [98; 99]. Targeted inhibition of angiogenesis in the subchondral bone represents a promising strategy for delaying the progression of OA. Numerous studies have elucidated the regulatory roles of TSPs in angiogenesis. Among the five members, TSP-1 and TSP-2 are renowned for their antiangiogenic effects, whereas the remaining three members exert proangiogenic effects. TSP-1, the first known endogenous anti-angiogenic protein, interacts with CD36 via TSRs and with CD47 via C-terminus, suppresses endothelial cell proliferation, migration, adhesion, and capillary-like structure formation, induces endothelial cell apoptosis through inhibiting NO/cGMP and vascular endothelial growth factor (VEGF) signaling pathway [8; 72; 100]. TSP-2 inhibits angiogenesis by suppressing Notch signaling pathway [101]. In contrast, Adognravi et. al reported that TSP-4 located within the lumen of growing vessels, and demonstrated that TSP-4 enhances endothelial cell proliferation, migration and adhesion through activating integrin α 2/ TGF- β /Smad3 signaling pathway. TSP-4 deficiency resulted in impaired angiogenesis, delayed wound healing, and delayed postnatal vasculature development in mice [102; 103]. In addition, TSP-4 overexpressing BMSCs

increased the proliferation, migration, and capillary formation of human umbilical vein endothelial cells (HUVECs) through activating TGF- β /Smad2/3 signaling pathway [104; 105]. The specific role of TSP-5 on angiogenesis has not been fully elucidated yet. However, Chou *et al.* have developed a stable and soluble variant of Angiopoietin-1 (Ang1) named recombinant COMP-Ang1 by substituting the N-terminal region of Ang1 with the short coiled-coil domain of TSP-5. Comparing to the naive Ang1, this modified variant exhibits enhanced potency in promoting wound healing and bone defect healing through increasing angiogenesis, osteoblasts differentiation and bone formation [106; 107; 108; 109]. Due to their distinctive antiangiogenic and proangiogenic properties, TSP proteins may serve as promising therapeutic targets for modulating subchondral bone angiogenesis in the progression of OA.

3.5. Thrombospondins in nerve sensitization

Pain is the primary reason patients with OA seek medical advice, as it limits joint function and reduces quality of life. For decades, the pain associated with OA has been attributed to nociceptive pain resulting from progressive joint degeneration, however, the clinical efficacy of pain management in OA patients remains suboptimal. Approximately 25% of the patients with OA reported experiencing pain characterized by neuropathic-like features, such as allodynia and hyperalgesia, suggesting the presence of central neural sensitization and additional mechanisms contributing to pain [110; 111; 112]. Microarray analyses of the dorsal root ganglia (DRG) from experimental OA mice also revealed the existence of neuro-inflammation and immune response in OA-related pain [113; 114]. The primary sources of nociceptive pain related to OA arise from the subchondral bone, synovium, meniscus, periarticular tendon, and ligaments, patients do not perceive cartilage degeneration due to its lack of innervation. Increased expressions of nociceptive neuron markers in the subchondral bone were observed from 1-week post-surgery in OA mice. The process of osteoclasts mediated bone resorption induces sensory innervation in the subchondral bone and increases hyper-excitability of DRG neurons by secreting Netrin-1 and nerve growth factor (NGF) [62; 115]. All TSPs, both trimeric and pentameric isoforms, interact with the calcium channel α -2- δ -1 subunit ($Ca_v\alpha_2\delta_1$) through their conserved EGF-like repeats, significantly increase excitatory synapse formation [116]. Among all, TSP-4 has been extensively studied in synaptogenesis and is identified as a potential biomarker for pain

assessment [117]. The serum concentrations of TSP-4 protein were substantially elevated in patients with lumbar disc herniation or coronary artery disease during the acute painful phase, subsequent procedures such as intervertebral discectomy or percutaneous coronary intervention led to a decrease of TSP-4 protein concentrations in serum [117]. Additionally, TSP-4, but not other TSPs expression is concurrent with the development of pain states and was positively correlated with VAS score [118]. Mechanistically, peripheral nerve injury induces the expression of TSP-4 in spinal cord and DRG. David Luo *et al.* demonstrated that TSP-4 directly interacts with its receptor $Ca_v\alpha_2\delta_1$ on the central terminals of sensory neurons, thereby promoting excitatory synaptogenesis and elevating sensory neurons excitability through decreasing high-voltage-activated (HVA) calcium current and increasing low-voltage-activated (LVA) calcium current [117; 119; 120; 121]. During the process of nerve sensitization, TSP-1 plays a multifaceted role by not only promoting the sensitization process but also participating in pain resolution mechanisms. TSP-1 deficient adult mice exhibit reduced proliferation of neural progenitor cells and impaired neuronal differentiation, indicating that TSP-1 may positively regulate neuronal differentiation and synapse formation [122]. Single-cell RNA sequencing result showed that TSP-1 expression was significantly increased in neutrophils and macrophages upon skin injury, and TSP-1 expression was positively correlated with the development of pain hypersensitivity. On the other hand, TSP-1 was shown to counteract prostaglandin E2 (PGE2)-induced sensitization of nociceptors, suggesting that TSP-1 is also implicated in the resolution of pain [123]. Although the specific role of TSP in OA-related pain has not been reported, it is reasonable to hypothesize that TSP proteins may be involved in neuropathic pain state in OA by promoting excitatory synaptogenesis.

4. Therapeutic Potential of thrombospondins in OA

4.1. Cartilage regeneration

Due to its avascular nature, low cell density, limited nutrient supply and low proliferative activity, cartilage exhibits restricted intrinsic repair and regenerative capability following defects and degeneration. MSCs-based cartilage repair offers a promising therapeutic approach for the cartilage defects [124]. However, the implanted seed cells failed to fully differentiate into mature hyaline cartilage; instead, they underwent ossification or fibrosis by activating the TGF- β /smad3 signaling pathway and

vascular invasion. Moreover, the implanted seed cells exhibit deficient capacity in ECM synthesis, resulting in inferior compressive mechanical property and elasticity [125; 126]. Thus, modifying seed cells is crucial to ensure their directional differentiation into chondrocytes, making it an important method for enhancing the success rate of cartilage repair. In addition to being a key glycoprotein within the cartilaginous ECM, TSP proteins also demonstrate the capacity to promote chondrogenic differentiation of MSCs, thereby facilitating effective cartilage regeneration (Table 3). Researchers from different groups employed lentivirus vector-mediated transfection of TSP-1 cDNA or recombinant TSP-1 in adipose-derived stem cells (ADSCs). Their investigation revealed that TSP-1 transfected ADSCs exhibited an increased anti-inflammatory property and chondrogenic differentiation, characterized by an increased content of collagen II and glycosaminoglycans, as well as a decreased expression of collagen I, RUNX2, OCN, and OPN [59; 127]. Similarly, TSP-2 enhances the chondrogenic differentiation of ADSCs and inhibits their hypertrophic maturation through the activation of PKCa, ERK, p38/MAPK and JAGGED1/NOTCH3 signaling pathways. Reversely, the depletion of TSP-2 expression leads to an increase in levels of hypertrophy-related genes (RUNX2 and MMP-13) and decrease in SOX9, Aggrecan and collagen II in the cartilage microspheres of MSCs [128; 129; 130; 131]. Furthermore, TSP-5 has also been reported to facilitate cartilage regeneration. The

up-regulation of Tsp-5 mRNA precedes Col2a1 by several days during chondrogenic differentiation of BMSCs. In a rabbit osteochondral defect model, the implantation of TSP-5-overexpressing MSCs loaded-biphasic scaffold significantly enhances hyaline cartilage formation and improves the mechanical properties of the newly formed cartilage [132; 133; 134; 135]. Compared to other members, TSP-3 and TSP-4 are relatively less studied in chondrogenic differentiation. Wan-Ju Li et. al established reprogrammed MSCs (Re-MSCs) through overexpressing pluripotency factors in synovial fluid-derived MSCs from OA patients (Pa-MSCs). The analysis of chondrogenesis revealed that Re-MSCs demonstrated a higher capacity for differentiation into mature articular cartilage, with an elevated expression of TSP-4 potentially accounting for the enhanced chondrogenic differentiation ability of Re-MSCs [136]. Collectively, TSP proteins exhibit promising potential in cartilage regeneration.

4.2. Pain management

Due to the lack of effective treatment options, analgesics remain the primary choice for managing OA symptoms so far. A stepped treatment approach including paracetamol, non-steroidal anti-inflammatory drugs (NSAIDs), steroids and opioids is employed based on the progression of the disease and severity of pain [139].

Table 3. Application of thrombospondins in cartilage regeneration

Gene	Cell source	Modification	<i>In-vivo</i> model	Outcome	Ref.
TSP-1	ADSCs	Lentivirus transfection	Subcutaneously transplanted the cell-scaffolds into nude mice for 8 weeks.	Reduced angiogenesis and osteogenic differentiation <i>in vitro</i> ; enhanced chondrogenic differentiation and inhibited osteogenic differentiation <i>in vivo</i> .	[127]
	BMSCs and ADSCs	Recombinant TSP-1 and siRNA transfection	Intraarticular injection of TSP-1-siRNA transfected ADSCs in CIOA mouse model.	Enhanced chondrogenic differentiation of BM-MSCs <i>in vitro</i> ; impaired chondroprotective after TSP-1 knockdown <i>in vivo</i>	[59]
	BMSCs	Combination of recombinant TSP-1 and recombinant osteogenic protein-1 (OP-1)	TSP-1 and OP-1 containing granules pressed into the microfracture holes in femoral trochlea of miniature pigs.	Inhibited angiogenesis <i>in vitro</i> ; inhibited chondrocyte hypertrophy, endochondral ossification and angiogenesis <i>in vivo</i> .	[137]
	Chondrosarcoma cell line HCS-2/8	Recombinant TSP-1 incorporated gelatin hydrogel	Implantation of rTSP-1 incorporated hydrogel into the microfracture holes in femoral trochlea of rat; Intraarticular injection of rTSP-1 incorporated hydrogel in MIA rat.	Enhanced proteoglycan synthesis <i>in vitro</i> ; enhanced cartilage regeneration in both surgically and chemically induced OA model.	[138]
TSP-2	BMSCs, hUCB-MSCs and chondroprogenitor cells	Treatment with synovial fluid from OA patients, recombinant TSP-2 and TSP-2-siRNA	Transplantation of rTSP-2 along with hyaluronic acid gel composite into the defect area in femoral trochlea of New Zealand white rabbits	Increased chondrogenic differentiation and inhibited hypertrophic differentiation, decreased ECM synthesis after TSP-2 knockdown <i>in vitro</i> ; increased cartilage regeneration <i>in vivo</i> .	[129; 130; 131]
	ADSCs	Treatment with recombinant TSP-2	Intraarticular injection of recombinant TSP-2 in ACLT induced OA rabbits.	Increased chondrogenic differentiation <i>in vitro</i> ; Increased cartilage regeneration and decreased inflammatory cytokines secretion <i>in vivo</i> .	[128]
TSP-5	BMSCs and mesenchymal fibroblasts (C3H10T1/2)	Plasmid and lipid DNA transfection	-	Enhanced chondrogenic differentiation and ECM organization and assembly <i>in vitro</i> .	[133; 134; 135]
	BMSCs	Adenovirus transfection	Transplantation of TSP-5 transfected BMSCs loaded biphasic scaffold into the defect area in femoral trochlea of New Zealand white rabbits.	Increased glycosaminoglycans synthesis <i>in vitro</i> ; enhanced osteochondral defect repair, cartilage regeneration, compressive modulus <i>in vivo</i> .	[132]

However, the side effects of these drugs are inevitable. It is crucial to recognize the molecular mechanisms responsible for initiating and sustaining the OA-related pain, with the aim of creating more potent therapeutic agents. Peripheral nerve injury induces up-regulation of TSP proteins in DRG that contribute to the development of neuropathic pain states [118], therefore, targeting TSPs could potentially serve as a therapeutic approach for pain management, including in OA patients. Intrathecal injection of TSP-4 antibodies, antisense oligodeoxynucleotides, or gabapentin reverses behavioral hypersensitivity and established allodynia in a rat model of spinal nerve ligation injury [118; 120]. Gabapentin, an antiepileptic and analgesic drug, competitively binds to $Ca_v\alpha_2\delta_1$ subunit, reduces its interaction with TSPs, which results in a reduction of calcium ions influx and inhibition of excitatory synapses formation (but not in already formed synapses) [116]. Gabapentin has been reported to improve disease-related pain in animal models of arthritis. In adjuvant-induced arthritis (AIA) rat model, gabapentin treatment led to a significant improvement in the general condition of the rats, including a reduction in paw swelling and an increase in paw withdrawal mechanical threshold (PWMT), reducing the expression of FGF2 and FGFR1 in the DRG through the upregulation of miR-15a [140]. In monosodium iodoacetate-induced arthritis (MIA) rat model, pregabalin significantly inhibited the neuronal responses to noxious electrical, mechanical, and thermal stimuli in OA rats, indicating its potential as an analgesic agent [139]. However, the analgesic effects of gabapentinoids in experimental arthritis are state-dependent. They are more effective in the presence of central sensitization, with a more pronounced impact on neuropathic pain conditions, but do not influence baseline sensory neuron excitability or sensory thresholds in control animals [120; 141]. The mechanisms underlying this effect, including whether it involves the inhibition of TSP-4-induced synaptogenesis and stabilization, remain to be elucidated. Moreover, the underlying mechanisms, safety, and feasibility of targeting TSP-4 as a therapeutic approach for OA-related pain require further investigation.

5. Conclusion and future perspectives

In conclusion, the glycoprotein family TSPs emerge as key regulators in the pathogenesis of OA. The presence of TSPs in articular cartilage facilitates the synthesis and assemble of ECM, promotes the chondrogenesis and chondrocyte proliferation, preserves the structural integrity of cartilage. Whereas

in the synovium and subchondral bone, TSPs may participate in inflammatory response, cell differentiation, angiogenesis, and excitatory synaptogenesis through various signaling pathways. The targeting of TSPs may hold significant potential in the delay of cartilage degeneration, promotion of cartilage regeneration, attenuation of synovial inflammation, inhibition of subchondral bone remodeling, and relieving of pain, all crucial aspects for the treatment of OA. Despite the promise, challenges remain. Further investigation is still necessary to elucidate the precise molecular mechanisms through which TSPs contribute to the development and progression of OA. These findings may encourage the development of molecules, antibodies, or other biological agents targeting specific TSP functions in OA treatment. Moreover, large-scale clinical studies are imperative to validate the sensitivity and accuracy of TSPs for diagnosing OA, as well as establish standardized detection methods for clinical application.

Acknowledgments

Funding

This work is supported by Natural Science Foundation of Shaanxi Province (2024JC-YBQN-0885) and postdoctoral research project funding of Shaanxi province (2023BSHGZZHQYXMZZ04).

Author contributions

Y.A. wrote the manuscript, H.Y. and P.X. revised the manuscript.

Competing Interests

The authors have declared that no competing interest exists.

References

1. Mahmoudian A, Lohmander L S, Mobasheri A, et al. Early-stage symptomatic osteoarthritis of the knee - time for action. *Nat Rev Rheumatol.* 2021; 17: 621-32.
2. Blagojevic M, Jinks C, Jeffery A, et al. Risk factors for onset of osteoarthritis of the knee in older adults: a systematic review and meta-analysis. *Osteoarthr Cartilage.* 2010; 18: 24-33.
3. Safiri S, Kolahi A, Smith E, et al. Global, regional and national burden of osteoarthritis 1990-2017: a systematic analysis of the Global Burden of Disease Study 2017. *Ann Rheum Dis.* 2020; 79: 819-28.
4. Pavone V, Vescio A, Turchetta M, et al. Injection-Based Management of Osteoarthritis of the Knee: A Systematic Review of Guidelines. *Front Pharmacol.* 2021; 12: 661805.
5. Hodgkinson T, Kelly D C, Curtin C M, et al. Mechanosignalling in cartilage: an emerging target for the treatment of osteoarthritis. *Nat Rev Rheumatol.* 2022; 18: 67-84.
6. Bonnans C, Chou J, Werb Z. Remodelling the extracellular matrix in development and disease. *Nat Rev Mol Cell Biol.* 2014; 15: 786-801.
7. Schwartz M A, Schaller M D, Ginsberg M H. Integrins: emerging paradigms of signal transduction. *Annu Rev Cell Dev Bi.* 1995; 11: 549-99.
8. Adams J C, Lawler J. The Thrombospondins. *Csh Perspect Biol.* 2011; 3: a9712.
9. Tucker R P, Adams J C. Molecular evolution of the Thrombospondin superfamily. *Semin Cell Dev Biol.* 2024; 155: 12-21.
10. Carminati L, Carlessi E, Longhi E, et al. Controlled extracellular proteolysis of thrombospondins. *Matrix Biol.* 2023; 119: 82-100.

11. Adams J, Lawler J. Extracellular matrix: the thrombospondin family. *Curr Biol.* 1993; 3: 188-90.
12. Narouz-Ott L, Maurer P, Nitsche D P, et al. Thrombospondin-4 Binds Specifically to Both Collagenous and Non-collagenous Extracellular Matrix Proteins via Its C-terminal Domains. *J Biol Chem.* 2000; 275: 37110-7.
13. Carlson C B, Lawler J, Mosher D F. Thrombospondins: from structure to therapeutics. *Cell Mol Life Sci.* 2008; 65: 672-86.
14. Chen H, Herndon M E, Lawler J. The cell biology of thrombospondin-1. *Matrix Biol.* 2000; 19: 597-614.
15. Alford A I, Hankenson K D. Thrombospondins modulate cell function and tissue structure in the skeleton. *Semin Cell Dev Biol.* 2024; 155: 58-65.
16. Hankenson K D, Sweetwyne M T, Shitaye H, et al. Thrombospondins and novel TSR-containing proteins, R-spondins, regulate bone formation and remodeling. *Curr Osteoporos Rep.* 2010; 8: 68-76.
17. Pan H, Lu X, Ye D, et al. The molecular mechanism of thrombospondin family members in cardiovascular diseases. *Front Cardiovasc Med.* 2024; 11: 1337586.
18. Vanhoutte D, Schips T G, Vo A, et al. Thbs1 induces lethal cardiac atrophy through PERK-ATF4 regulated autophagy. *Nat Commun.* 2021; 12: 3928.
19. Murphy-Ullrich J E, Suto M J. Thrombospondin-1 regulation of latent TGF- β activation: A therapeutic target for fibrotic disease. *Matrix Biol.* 2018; 68-69: 28-43.
20. Amend S R, Uluckan O, Hurchla M, et al. Thrombospondin-1 Regulates Bone Homeostasis Through Effects on Bone Matrix Integrity and Nitric Oxide Signaling in Osteoclasts. *J Bone Miner Res.* 2015; 30: 106-15.
21. Taylor D K, Meganck J A, Terkhorst S, et al. Thrombospondin-2 Influences the Proportion of Cartilage and Bone During Fracture Healing. *J Bone Miner Res.* 2009; 24: 1043-54.
22. Manley E, Perosky J E, Khoury B M, et al. Thrombospondin-2 deficiency in growing mice alters bone collagen ultrastructure and leads to a brittle bone phenotype. *J Appl Physiol.* 2015; 119: 872-81.
23. Miedel E, Dishowitz M I, Myers M H, et al. Disruption of thrombospondin-2 accelerates ischemic fracture healing. *J Orthop Res.* 2013; 31: 935-43.
24. Hankenson K D, Hormuzdi S G, Meganck J A, et al. Mice with a Disruption of the Thrombospondin 3 Gene Differ in Geometric and Biomechanical Properties of Bone and Have Accelerated Development of the Femoral Head. *Mol Cell Biol.* 2005; 25: 5599-606.
25. Posey K L, Hankenson K, Veerisetty A C, et al. Skeletal Abnormalities in Mice Lacking Extracellular Matrix Proteins, Thrombospondin-1, Thrombospondin-3, Thrombospondin-5, and Type IX Collagen. *Am J Pathol.* 2008; 172: 1664-74.
26. Jeschke A, Bonitz M, Simon M, et al. Deficiency of Thrombospondin-4 in Mice Does Not Affect Skeletal Growth or Bone Mass Acquisition, but Causes a Transient Reduction of Articular Cartilage Thickness. *Plos One.* 2015; 10: e144272.
27. Hecht J T, Nelson L D, Crowder E, et al. Mutations in exon 17B of cartilage oligomeric matrix protein (COMP) cause pseudoachondroplasia. *Nat Genet.* 1995; 10: 325-9.
28. Ulrich-Vinther M, Maloney M D, Schwarz E M, et al. Articular Cartilage Biology. *J Am Acad Orthop Sur.* 2003; 11: 421-30.
29. Zhang M, Theleman J L, Lygrisse K A, et al. Epigenetic Mechanisms Underlying the Aging of Articular Cartilage and Osteoarthritis. *Gerontology (Basel).* 2019; 65: 387-96.
30. Alcaide-Ruggiero L, Cugat R, Domínguez J M. Proteoglycans in Articular Cartilage and Their Contribution to Chondral Injury and Repair Mechanisms. *Int J Mol Sci.* 2023; 24: 10824.
31. Whitelock J M, Melrose J, Iozzo R V. Diverse Cell Signaling Events Modulated by Perlecan. *Biochemistry.* 2008; 47: 11174-83.
32. Han B, Li Q, Wang C, et al. Decorin Regulates the Aggrecan Network Integrity and Biomechanical Functions of Cartilage Extracellular Matrix. *Acs Nano.* 2019; 13: 11320-33.
33. Andrés Sastre E, Maly K, Zhu M, et al. Spatiotemporal distribution of thrombospondin-4 and -5 in cartilage during endochondral bone formation and repair. *Bone.* 2021; 150: 115999.
34. Kyriakides T R, Zhu Y, Yang Z, et al. The Distribution of the Matricellular Protein Thrombospondin 2 in Tissues of Embryonic and Adult Mice. *J Histochem Cytochem.* 1998; 46: 1007-15.
35. Pfander D, Cramer T, Deuerling D, et al. Expression of thrombospondin-1 and its receptor CD36 in human osteoarthritic cartilage. *Ann Rheum Dis.* 2000; 59: 448-54.
36. Iruela Arispe M L, Liska D J, Sage E H, et al. Differential expression of thrombospondin 1, 2, and 3 during murine development. *Dev Dynam.* 1993; 197: 40-56.
37. Maly K, Andres Sastre E, Farrell E, et al. COMP and TSP-4: Functional Roles in Articular Cartilage and Relevance in Osteoarthritis. *Int J Mol Sci.* 2021; 22: 2242.
38. Li H, Huang L, Zhao R, et al. TSP-1 increases autophagy level in cartilage by upregulating HSP27 which delays progression of osteoarthritis. *Int Immunopharmacol.* 2024; 128: 111475.
39. Xia Y, Dobaczewski M, Gonzalez-Quesada C, et al. Endogenous Thrombospondin 1 Protects the Pressure-Overloaded Myocardium by Modulating Fibroblast Phenotype and Matrix Metabolism. *Hypertension.* 2011; 58: 902-11.
40. Maly K, Schaible I, Riegger J, et al. The Expression of Thrombospondin-4 Correlates with Disease Severity in Osteoarthritic Knee Cartilage. *Int J Mol Sci.* 2019; 20: 447.
41. Hsieh J L, Shen P C, Shiau A L, et al. Intraarticular gene transfer of thrombospondin-1 suppresses the disease progression of experimental osteoarthritis. *J Orthop Res.* 2010; 28: 1300-6.
42. Chou C, Jain V, Gibson J, et al. Synovial cell cross-talk with cartilage plays a major role in the pathogenesis of osteoarthritis. *Sci Rep.* 2020; 10: 10868.
43. Orr C, Vieira-Sousa E, Boyle D L, et al. Synovial tissue research: a state-of-the-art review. *Nat Rev Rheumatol.* 2017; 13: 463-75.
44. Li Z A, Sant S, Cho S K, et al. Synovial joint-on-a-chip for modeling arthritis: progress, pitfalls, and potential. *Trends Biotechnol.* 2023; 41: 511-27.
45. Robinson W H, Lepus C M, Wang Q, et al. Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis. *Nat Rev Rheumatol.* 2016; 12: 580-92.
46. Huang Z Y, Luo Z Y, Cai Y R, et al. Single cell transcriptomics in human osteoarthritis synovium and in silico deconvoluted bulk RNA sequencing. *Osteoarthr Cartilage.* 2022; 30: 475-80.
47. Sebastian A, Hum N R, McCool J L, et al. Single-cell RNA-Seq reveals changes in immune landscape in post-traumatic osteoarthritis. *Front Immunol.* 2022; 13: 938075.
48. Knights A J, Farrell E C, Ellis O M, et al. Synovial fibroblasts assume distinct functional identities and secrete R-spondin 2 in osteoarthritis. *Ann Rheum Dis.* 2023; 82: 272-82.
49. Rico M C, Castaneda J L, Manns J M, et al. Amelioration of inflammation, angiogenesis and CTGF expression in an arthritis model by a TSP1-derived peptide treatment. *J Cell Physiol.* 2007; 211: 504-12.
50. McMorrow J P, Crean D, Gogarty M, et al. Tumor Necrosis Factor Inhibition Modulates Thrombospondin-1 Expression in Human Inflammatory Joint Disease through Altered NR4A2 Activity. *Am J Pathol.* 2013; 183: 1243-57.
51. Rico M C, Manns J M, Drihan J B, et al. Thrombospondin-1 and transforming growth factor beta are pro-inflammatory molecules in rheumatoid arthritis. *Transl Res.* 2008; 152: 95-8.
52. Hou C H, Tang C H, Chen P C, et al. Thrombospondin 2 Promotes IL-6 Production in Osteoarthritis Synovial Fibroblasts via the PI3K/AKT/NF-kappaB Pathway. *J Inflamm Res.* 2021; 14: 5955-67.
53. Zhang H, Lin C, Zeng C, et al. Synovial macrophage M1 polarisation exacerbates experimental osteoarthritis partially through R-spondin-2. *Ann Rheum Dis.* 2018; 77: 1524-34.
54. Rahman M T, Muppala S, Wu J, et al. Effects of thrombospondin-4 on pro-inflammatory phenotype differentiation and apoptosis in macrophages. *Cell Death Dis.* 2020; 11: 53.
55. Li Q, Fu X, Yuan J, et al. Contribution of Thrombospondin-1 and -2 to Lipopolysaccharide-Induced Acute Respiratory Distress Syndrome. *Mediat Inflamm.* 2021; 2021: 1-22.
56. Gwag T, Reddy Mooli R G, Li D, et al. Macrophage-derived thrombospondin 1 promotes obesity-associated non-alcoholic fatty liver disease. *JHEP Rep.* 2021; 3: 100193.
57. Li Y, Qi X, Tong X, et al. Thrombospondin 1 activates the macrophage Toll-like receptor 4 pathway. *Cell Mol Immunol.* 2013; 10: 506-12.
58. Chen X, Yang B, Tian J, et al. Dental Follicle Stem Cells Ameliorate Lipopolysaccharide-Induced Inflammation by Secreting TGF- β 3 and TSP-1 to Elicit Macrophage M2 Polarization. *Cell Physiol Biochem.* 2018; 51: 2290-308.
59. Maumus M, Manferdini C, Toupet K, et al. Thrombospondin-1 Partly Mediates the Cartilage Protective Effect of Adipose-Derived Mesenchymal Stem Cells in Osteoarthritis. *Front Immunol.* 2017; 8: 1638.
60. Xiao C, Lv C, Sun S, et al. TSP1 is the essential domain of SEMA5A involved in pannus formation in rheumatoid arthritis. *Rheumatology.* 2021; 60: 5833-42.
61. Zhao F, Dong J, Guo J, et al. Inhibiting role of long non-coding RNA LINC01197 in inflammation in rheumatoid arthritis through the microRNA-150/THBS2 axis. *Exp Cell Res.* 2020; 394: 112136.
62. Hu Y, Chen X, Wang S, et al. Subchondral bone microenvironment in osteoarthritis and pain. *Bone Res.* 2021; 9: 20.
63. Li G, Yin J, Gao J, et al. Subchondral bone in osteoarthritis: insight into risk factors and microstructural changes. *Arthritis Res Ther.* 2013; 15: 223.
64. Burr D B, Gallant M A. Bone remodelling in osteoarthritis. *Nat Rev Rheumatol.* 2012; 8: 665-73.
65. Zhu S, Zhu J, Zhen G, et al. Subchondral bone osteoclasts induce sensory innervation and osteoarthritis pain. *J Clin Invest.* 2019; 129: 1076-93.
66. Mostafa R E, Salama A A A. Eplerenone modulates the inflammatory response in monosodium iodoacetate-induced knee osteoarthritis in rats: Involvement of RANKL/OPG axis. *Life Sci.* 2023; 316: 121405.
67. Wu W, Song K, Chen G, et al. Ganoderic acid A improves osteoarthritis by regulating RANKL/OPG ratio. *Chem Biol Drug Des.* 2022; 100: 313-9.
68. Hu W, Chen Y, Dou C, et al. Microenvironment in subchondral bone: predominant regulator for the treatment of osteoarthritis. *Ann Rheum Dis.* 2021; 80: 413-22.
69. Teitelbaum S L, Ross F P. Genetic regulation of osteoclast development and function. *Nat Rev Genet.* 2003; 4: 638-49.
70. Zhang H, Wang L, Cui J, et al. Maintaining hypoxia environment of subchondral bone alleviates osteoarthritis progression. *Sci Adv.* 2023; 9: eabo7868.
71. Koduru S V, Sun B H, Walker J M, et al. The contribution of cross-talk between the cell-surface proteins CD36 and CD47-TSP-1 in osteoclast formation and function. *J Biol Chem.* 2018; 293: 15055-69.
72. Singla B, Aithbathula R V, Pervaiz N, et al. CD47 Activation by Thrombospondin-1 in Lymphatic Endothelial Cells Suppresses

- Lymphangiogenesis and Promotes Atherosclerosis. *Arterioscler Thromb Vasc Biol.* 2023; 43: 1234-50.
73. Dawson D W, Pearce S F A, Zhong R, et al. CD36 Mediates the In Vitro Inhibitory Effects of Thrombospondin-1 on Endothelial Cells. *J Cell Biol.* 1997; 138: 707-17.
 74. Kukreja A, Radfar S, Sun B, et al. Dominant role of CD47–thrombospondin-1 interactions in myeloma-induced fusion of human dendritic cells: implications for bone disease. *Blood.* 2009; 114: 3413-21.
 75. Liu J, Lee C, Tsai M, et al. Thrombospondin 2 promotes tumor metastasis by inducing matrix metalloproteinase-13 production in lung cancer cells. *Biochem Pharmacol.* 2018; 155: 537-46.
 76. Wang M, Chao C, Chen P, et al. Thrombospondin enhances RANKL-dependent osteoclastogenesis and facilitates lung cancer bone metastasis. *Biochem Pharmacol.* 2019; 166: 23-32.
 77. Maruotti N, Corrado A, Cantatore F P. Osteoblast role in osteoarthritis pathogenesis. *J Cell Physiol.* 2017; 232: 2957-63.
 78. Yu D, Xu J, Liu F, et al. Subchondral bone changes and the impacts on joint pain and articular cartilage degeneration in osteoarthritis. *Clin Exp Rheumatol.* 2016; 34: 929-34.
 79. Mansell J P, Bailey A J. Abnormal cancellous bone collagen metabolism in osteoarthritis. *J Clin Invest.* 1998; 101: 1596-603.
 80. Li B, Aspden R M. Composition and Mechanical Properties of Cancellous Bone from the Femoral Head of Patients with Osteoporosis or Osteoarthritis. *J Bone Miner Res.* 1997; 12: 641-51.
 81. Chen G, Deng C, Li Y. TGF- β and BMP Signaling in Osteoblast Differentiation and Bone Formation. *Int J Biol Sci.* 2012; 8: 272-88.
 82. Zhen G, Wen C, Jia X, et al. Inhibition of TGF- β signaling in mesenchymal stem cells of subchondral bone attenuates osteoarthritis. *Nat Med.* 2013; 19: 704-12.
 83. Khalil N. TGF-beta: from latent to active. *Microbes Infect.* 1999; 1: 1255-63.
 84. Na W, Kang M, Park S, et al. Aesculetin Accelerates Osteoblast Differentiation and Matrix-Vesicle-Mediated Mineralization. *Int J Mol Sci.* 2021; 22: 12391.
 85. Hankenson K D, Bornstein P. The secreted protein thrombospondin 2 is an autocrine inhibitor of marrow stromal cell proliferation. *J Bone Miner Res.* 2002; 17: 415-25.
 86. Hankenson K D, Bain S D, Kyriakides T R, et al. Increased marrow-derived osteoprogenitor cells and endosteal bone formation in mice lacking thrombospondin 2. *J Bone Miner Res.* 2000; 15: 851-62.
 87. Alford A I, Golicz A Z, Cathey A L, et al. Thrombospondin-2 facilitates assembly of a type-I collagen-rich matrix in marrow stromal cells undergoing osteoblastic differentiation. *Connect Tissue Res.* 2013; 54: 275-82.
 88. Shitaye H S, Terkhorn S P, Combs J A, et al. Thrombospondin-2 is an endogenous adipocyte inhibitor. *Matrix Biol.* 2010; 29: 549-56.
 89. Hankenson K D, James I, Apone S, et al. Increased osteoblastogenesis and decreased bone resorption protect against ovariectomy-induced bone loss in thrombospondin-2-null mice. *Matrix Biol.* 2005; 24: 362-70.
 90. Zhu L, Liu Y, Wang A, et al. Application of BMP in Bone Tissue Engineering. *Front Bioeng Biotech.* 2022; 10: 810880.
 91. Park S, Kim K, Kim S, et al. BMP-2 Gene Delivery-Based Bone Regeneration in Dentistry. *Pharmaceutics.* 2019; 11: 393.
 92. Haudenschild D R, Hong E, Yik J H N, et al. Enhanced Activity of Transforming Growth Factor β 1 (TGF- β 1) Bound to Cartilage Oligomeric Matrix Protein. *J Biol Chem.* 2011; 286: 43250-8.
 93. Ishida K, Acharya C, Christiansen B A, et al. Cartilage oligomeric matrix protein enhances osteogenesis by directly binding and activating bone morphogenetic protein-2. *Bone.* 2013; 55: 23-35.
 94. Sanchez C, Mazzucchelli G, Lambert C, et al. Comparison of secretome from osteoblasts derived from sclerotic versus non-sclerotic subchondral bone in OA: A pilot study. *Plos One.* 2018; 13: e194591.
 95. Kuttapitiya A, Assi L, Laing K, et al. Microarray analysis of bone marrow lesions in osteoarthritis demonstrates upregulation of genes implicated in osteochondral turnover, neurogenesis and inflammation. *Ann Rheum Dis.* 2017; 76: 1764-73.
 96. Cui Z, Crane J, Xie H, et al. Halofuginone attenuates osteoarthritis by inhibition of TGF- β activity and H-type vessel formation in subchondral bone. *Ann Rheum Dis.* 2016; 75: 1714-21.
 97. Liu Y, Xie H, Shen B. Type H vessels—a bridge connecting subchondral bone remodelling and articular cartilage degeneration in osteoarthritis development. *Rheumatology (Oxford).* 2023; 62: 1436-44.
 98. Walsh D A, Bonnet C S, Turner E L, et al. Angiogenesis in the synovium and at the osteochondral junction in osteoarthritis. *Osteoarthritis Cartilage.* 2007; 15: 743-51.
 99. Walsh D A, McWilliams D F, Turley M J, et al. Angiogenesis and nerve growth factor at the osteochondral junction in rheumatoid arthritis and osteoarthritis. *Rheumatology (Oxford).* 2010; 49: 1852-61.
 100. Isenberg J S, Frazier W A, Roberts D D. Thrombospondins: from structure to therapeutics. *Cell Mol Life Sci.* 2008; 65: 728-42.
 101. Pan W, Song X, Hu Q, et al. TSP2 acts as a suppressor of cell invasion, migration and angiogenesis in medulloblastoma by inhibiting the Notch signaling pathway. *Brain Res.* 2019; 1718: 223-30.
 102. Muppala S, Frolova E, Xiao R, et al. Proangiogenic Properties of Thrombospondin-4. *Arterioscler Thromb Vasc Biol.* 2015; 35: 1975-86.
 103. Muppala S, Xiao R, Krukovets I, et al. Thrombospondin-4 mediates TGF- β -induced angiogenesis. *Oncogene.* 2017; 36: 5189-98.
 104. Zhang Q, Zhou M, Wu X, et al. Promoting therapeutic angiogenesis of focal cerebral ischemia using thrombospondin-4 (TSP4) gene-modified bone marrow stromal cells (BMSCs) in a rat model. *J Transl Med.* 2019; 17: 111.
 105. Zhang Q, Wang T, Wu X, et al. Thrombospondin-4 (TSP4) gene-modified bone marrow stromal cells (BMSCs) promote the effect of therapeutic angiogenesis in critical limb ischemia (CLI) of diabetic rats. *Biochem Bioph Res Co.* 2020; 532: 231-8.
 106. Cho C, Sung H, Kim K, et al. COMP-Angiopoietin-1 Promotes Wound Healing through Enhanced Angiogenesis, Lymphangiogenesis, and Blood Flow in a Diabetic Mouse Model. *Proc Natl Acad Sci U S A.* 2006; 103: 4946-51.
 107. Kim S, Lee H, Ahn K, et al. COMP-Angiopoietin-1 Promotes Cavernous Angiogenesis in a Type 2 Diabetic Rat Model. *J Korean Med Sci.* 2013; 28: 725.
 108. Jeong B, Kim H, Bae I, et al. COMP-Ang1, a chimeric form of Angiopoietin 1, enhances BMP2-induced osteoblast differentiation and bone formation. *Bone.* 2010; 46: 479-86.
 109. Lim S S, Kook S H, Bhattarai G, et al. Local delivery of COMP-angiopoietin 1 accelerates new bone formation in rat calvarial defects. *J Biomed Mater Res A.* 2015; 103: 2942-51.
 110. Thakur M, Dickenson A H, Baron R. Osteoarthritis pain: nociceptive or neuropathic? *Nat Rev Rheumatol.* 2014; 10: 374-80.
 111. Bensen G P, Rogers A C, Leifer V P, et al. Does gabapentin provide benefit for patients with knee OA? A benefit-harm and cost-effectiveness analysis. *Osteoarthritis Cartilage.* 2023; 31: 279-90.
 112. French H P, Smart K M, Doyle F. Prevalence of neuropathic pain in knee or hip osteoarthritis: A systematic review and meta-analysis. *Semin Arthritis Rheum.* 2017; 47: 1-8.
 113. Miller R E, Tran P B, Ishihara S, et al. Microarray analyses of the dorsal root ganglia support a role for innate neuro-immune pathways in persistent pain in experimental osteoarthritis. *Osteoarthritis Cartilage.* 2020; 28: 581-92.
 114. Raoof R, Martin Gil C, Lafeber F P J G, et al. Dorsal Root Ganglia Macrophages Maintain Osteoarthritis Pain. *J Neurosci.* 2021; 41: 8249-61.
 115. Ni S, Ling Z, Wang X, et al. Sensory innervation in porous endplates by Netrin-1 from osteoclasts mediates PGE2-induced spinal hypersensitivity in mice. *Nat Commun.* 2019; 10: 5643.
 116. Eroglu C, Allen N J, Susman M W, et al. Gabapentin Receptor α 2delta-1 Is a Neuronal Thrombospondin Receptor Responsible for Excitatory CNS Synaptogenesis. *Cell.* 2009; 139: 380-92.
 117. Wu Y, Yang M, Xu X, et al. Thrombospondin 4, a mediator and candidate indicator of pain. *Eur J Cell Biol.* 2024; 103: 151395.
 118. Kim D S, Li K W, Boroujerdi A, et al. Thrombospondin-4 contributes to spinal sensitization and neuropathic pain states. *J Neurosci.* 2012; 32: 8977-87.
 119. Yu Y P, Gong N, Kweon T D, et al. Gabapentin prevents synaptogenesis between sensory and spinal cord neurons induced by thrombospondin-4 acting on pre-synaptic $Ca_v\alpha_2\delta_1$ subunits and involving T-type Ca^{2+} channels. *Brit J Pharmacol.* 2018; 175: 2348-61.
 120. Park J, Yu Y P, Zhou C, et al. Central Mechanisms Mediating Thrombospondin-4-induced Pain States. *J Biol Chem.* 2016; 291: 13335-48.
 121. Crosby N D, Zaucke F, Kras J V, et al. Thrombospondin-4 and excitatory synaptogenesis promote spinal sensitization after painful mechanical joint injury. *Exp Neurol.* 2015; 264: 111-20.
 122. Lu Z, Kipnis J. Thrombospondin 1—a key astrocyte-derived neurogenic factor. *FASEB J.* 2010; 24: 1925-34.
 123. Jain A, Gyori B M, Hakim S, et al. Nociceptor-immune interactomes reveal insult-specific immune signatures of pain. *Nat Immunol.* 2024; 25: 1296-305.
 124. Xiang X, Zhu S, He H, et al. Mesenchymal stromal cell-based therapy for cartilage regeneration in knee osteoarthritis. *Stem Cell Res Ther.* 2022; 13: 14.
 125. Muthu S, Korpershoek J V, Novais E J, et al. Failure of cartilage regeneration: emerging hypotheses and related therapeutic strategies. *Nat Rev Rheumatol.* 2023; 19: 403-16.
 126. Varela-Eirin M, Loureiro J, Fonseca E, et al. Cartilage regeneration and ageing: Targeting cellular plasticity in osteoarthritis. *Ageing Res Rev.* 2018; 42: 56-71.
 127. Xie A, Xue J, Shen G, et al. Thrombospondin-1 inhibits ossification of tissue engineered cartilage constructed by ADSCs. *Am J Transl Res.* 2017; 9: 3487-98.
 128. Shin K, Cha Y, Ban Y H, et al. Anti-osteoarthritis effect of a combination treatment with human adipose tissue-derived mesenchymal stem cells and thrombospondin 2 in rabbits. *World J Stem Cells.* 2019; 11: 1115-29.
 129. Jeong S Y, Ha J, Lee M, et al. Autocrine Action of Thrombospondin-2 Determines the Chondrogenic Differentiation Potential and Suppresses Hypertrophic Maturation of Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells. *Stem Cells.* 2015; 33: 3291-303.
 130. Jeong S Y, Kim D H, Ha J, et al. Thrombospondin-2 secreted by human umbilical cord blood-derived mesenchymal stem cells promotes chondrogenic differentiation. *Stem Cells (Dayton, Ohio).* 2013; 31: 2136-48.
 131. Niu J, Feng F, Zhang S, et al. Thrombospondin-2 Couples Pressure-Promoted Chondrogenesis through NF- κ B Signaling. *Tissue Eng Regen Med.* 2023; 20: 753-66.
 132. Wang C, Liu G, Zhang W, et al. Cartilage oligomeric matrix protein improves in vivo cartilage regeneration and compression modulus by enhancing matrix assembly and synthesis. *Colloids Surf B Biointerfaces.* 2017; 159: 518-26.
 133. Guo P, Shi Z, Liu A, et al. Cartilage oligomeric matrix protein gene multilayers inhibit osteogenic differentiation and promote chondrogenic differentiation of mesenchymal stem cells. *Int J Mol Sci.* 2014; 15: 20117-33.
 134. Haleem-Smith H, Calderon R, Song Y, et al. Cartilage oligomeric matrix protein enhances matrix assembly during chondrogenesis of human mesenchymal stem cells. *J Cell Biochem.* 2012; 113: 1245-52.

135. Kipnes J, Carlberg A L, Lored G A, et al. Effect of cartilage oligomeric matrix protein on mesenchymal chondrogenesis in vitro. *Osteoarthr Cartilage*. 2003; 11: 442-54.
136. Walczak B E, Jiao H, Lee M, et al. Reprogrammed Synovial Fluid-Derived Mesenchymal Stem/Stromal Cells Acquire Enhanced Therapeutic Potential for Articular Cartilage Repair. *Cartilage*. 2021; 13: 530S-543S.
137. Gelse K, Klinger P, Koch M, et al. Thrombospondin-1 prevents excessive ossification in cartilage repair tissue induced by osteogenic protein-1. *Tissue Eng Pt A*. 2011; 17: 2101-12.
138. Abd El Kader T, Kubota S, Nishida T, et al. The regenerative effects of CCN2 independent modules on chondrocytes in vitro and osteoarthritis models in vivo. *Bone*. 2014; 59: 180-8.
139. Rahman W, Bauer C S, Bannister K, et al. Descending Serotonergic Facilitation and the Antinociceptive Effects of Pregabalin in a Rat Model of Osteoarthritic Pain. *Mol Pain*. 2009; 5: 45.
140. Sun D, Yang J, Wang D, et al. Gabapentin regulates expression of FGF2 and FGFR1 in dorsal root ganglia via microRNA-15a in the arthritis rat model. *J Orthop Sci*. 2017; 22: 1112-9.
141. Park H J, Sandor K, McQueen J, et al. The effect of gabapentin and ketorolac on allodynia and conditioned place preference in antibody-induced inflammation. *Eur J Pain*. 2016; 20: 917-25.